infertility
Conditions
Interventions
Experimental group:Angeltan 200mg QD*1d, 200mg BID*1d, 200mg TID*15d, vaginal administration
Control group:Angeltan 200mg TID for vaginal administration
Sponsors
Reproductive Medicine Center, The First Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
Female
Age
18 Years to 38 Years
Inclusion criteria
Inclusion criteria: 1.IVF or ICSI and fresh embryo transfer cycle; 2.Premenopausal females, aged 18 to 38 years; 3.Total oocytes retrieved cycle = 1.1ng/ml, bFSH 5; 5.BMI= 7mm; 7.Antagonists or long - term protocol were used to induce ovulation; 8.Signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with intrauterine abnormalities, including: history of uterine adhesiolysis, history of mediastinal or mediastinal resection, unilocular uterine and submucosal fibroids without surgical treatment; 2.Patients with a history of recurrent spontaneous abortion, recurrent spontaneous abortion was defined as three or more consecutive pregnancies loss (including biochemical pregnancy abortion and clinical pregnancy loss); 3.Three or more times of embryo transfer without clinical pregnancy; 4.Patients with hydrosalpinx; 5.Patients with uncontrolled hyperprolactinemia, hypothyroidism and severe internal and surgical diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| live birth rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| chorionic gonadotropin positive rate;clinical pregnancy rate;Clinical pregnancy miscarriage rate;Continuing pregnancy rate;Ectopic pregnancy rate;birth weight;Maternal and Infant Complications;The incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactXu Yanwen
Reproductive Medicine Center, The First Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed